Lauren Schroeder

Lauren Schroeder joined Immatics in August 2024 and is responsible for the strategic development and execution of marketing initiatives. Her role is crucial in ensuring the successful positioning of Immatics’ lead cell therapy product candidate, ACTengine® IMA203, driving market readiness and launch execution to maximize its impact on patients’ lives. With nearly two decades of experience in pharmaceutical marketing, Lauren has a proven track record of eight major oncology drug launches. Notably, she played a major role in the groundbreaking approval of YESCARTA, the first-ever cell therapy for adults. Her career encompasses key roles with three innovative start-ups—Pharmacyclics (Abbvie), Kite Pharma (Gilead), and Mirati (BMS)—where she was instrumental in delivering transformative therapies to patients with critical needs. As a recent cancer caregiver, Lauren’s personal experience has further fueled her dedication to advancing breakthrough treatments for solid tumor cancers, aligning her passion with Immatics’ mission to bring life-changing cell therapies to patients. Lauren Schroeder has an BMA in Pharma Marketing from St. Joseph’s University.